MARIA SAINZ - Corporate Board Profile

Orthofix Medical Inc.

Filing Date	Source Excerpt
2011-07-01	Ms. Sainz, 45, became a non-executive Director of Orthofix International N.V. in June 2008. ... Ms. Sainz provides the Board with significant experience in the medical device industry, as well as insight into international markets. ... Dr. Jordan, Mr. Mainelli and Ms. Sainz currently serve as members of the Compensation Committee. ... Messrs. Weisshaar and Mainelli and Ms. Sainz currently serve as members of the Audit Committee. ... The Board of Directors unanimously recommends that you vote "FOR" the election of the foregoing nominees for director.
2013-04-30	Maria Sainz, 47, became a director of Orthofix in November 2012. Ms. Sainz currently serves as a member of the Compensation Committee. The following table provides information regarding director compensation during the fiscal year ended December 31, 2012. Maria Sainz Fees Earned or Paid in Cash: $5,543, Restricted Stock Awards: 3,500 shares, Grant Date Fair Value of Restricted Stock Awards: $130,795, Total: $136,338.
2014-04-30	Ms. Sainz, 48, became a director in November 2012. She serves on the Audit and Finance Committee and the Compliance Committee. She received $60,000 in fees and $76,230 in restricted stock awards, totaling $136,230.
2015-04-30	Ms. Sainz, 49, became a director of Orthofix in November 2012, after previously having served on our Board from June 2008 to September 2011. In April 2012, she became the President and Chief Executive Officer, and a director, of CardioKinetix Inc., a heart failure related medical device company. From April 2008 to October 2011, she was President and Chief Executive Officer of Concentric Medical, Inc., a company developing and commercializing devices to perform mechanical clot removal post-stroke, which was sold to Stryker Corporate in October 2011. Upon this acquisition, she served as General Manager of the Stryker Neurovascular business unit until April 2012. From 2003 to 2006, she was the President of the Cardiac Surgery division of Guidant Corporation. After Boston Scientific acquired Guidant, Ms. Sainz led the integration process for both the Cardiac Surgery and European Cardiac Rhythm Management business of Guidant into Boston Scientific. Between 2001 and 2003, Ms. Sainz was the Vice President of Global Marketing – Vascular Intervention of Guidant. Ms. Sainz earned a Bachelor and Masters of Arts from the Universidad Complutense de Madrid and a Master's Degree in International Management from American Graduate School of International Management. Ms. Sainz has served as a director of publicly-traded medical device companies The Spectranetics Corporation and MRI Interventions, Inc. since November 2010 and January 2014, respectively. Ms. Sainz has also been serving on the Board of Directors of Halyard Health, Inc. since February 2015.
2016-04-29	Ms. Sainz, 50, became a director of Orthofix in November 2012. She served as Chair of the Compliance Committee. ... Maria Sainz Fees Earned or Paid in Cash ($) 70,000, Restricted Stock Awards (Number of Shares Granted) 5,000, Grant Date Fair Value of Restricted Stock Awards ($) 165,600, Total ($) 235,600.
2017-04-28	Ms. Sainz, 51, became a director of Orthofix in November 2012. ... Ms. Sainz provides the Board with significant experience in the medical device industry, as well as insight into international markets. ... Ms. Sainz serves on the Audit and Finance Committee and is Chair of the Compliance Committee. ... The following table provides information regarding the 2016 compensation of non-employee directors. Maria Sainz: Fees Earned or Paid in Cash ($) 70,000, Restricted Stock Awards (Number of Shares Granted) 3,950, Total ($) 245,341.
2019-04-29	Ms. Sainz, 53, became a director of Orthofix in November 2012. ... Ms. Sainz currently serves as Chair of the Compliance and Ethics Committee. ... Maria Sainz 70,000 fees earned or paid in cash, 2,900 restricted stock awards, 164,952 grant date fair value of restricted stock awards, total 234,952.
2020-04-29	Ms. Sainz, 54, became a director of Orthofix in November 2012... Ms. Sainz provides the Board with significant experience in the medical device industry, as well as insight into international markets. The Board also values the perspective she brings from her current position as a chief executive officer. ... The following table provides information regarding the 2019 compensation of non-employee directors. ... Maria Sainz 80,000 fees earned in cash, 3,431 restricted stock awards, 174,981 grant date fair value of restricted stock awards, total 254,981.
2021-04-29	Maria Sainz Ms. Sainz, 55, became a director of Orthofix in November 2012. Ms. Sainz serves as Chair of the Compliance and Ethics Committee and member of the Compensation Committee. The following table provides information regarding the 2020 compensation of non-employee directors. Maria Sainz Fees Earned or Paid in Cash: 77,333 Restricted Stock Unit Awards: 4,588 Grant Date Fair Value of Restricted Stock Awards: 175,032 Total: 252,365 Ms. Sainz is not standing for re-election at the Annual Meeting.